Monoclonal antibody:
Treatment of advanced (unresectable or metastatic)
melanoma, non-small cell lung cancer, renal cell
carcinoma, classical Hodgkin lymphoma, squamous
cell cancer of the head and neck and urothelial
carcinoma
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use
Metabolism
The metabolic pathway of nivolumab has not been
investigated. It is expected to be degraded into small
peptides and amino acids via catabolic pathways in the
same way as endogenous IgG
